News | January 21, 2014

ASA releases recommendations for pain medicine, imaging


January 21, 2014 — As part of ABIM Foundation’s Choosing Wisely campaign, the American Society of Anesthesiologists  (ASA) released its second list of five targeted, evidence-based recommendations to support conversations between patients and physician anesthesiologists about what care is really necessary.
 
  1. Avoid imaging studies for acute low-back pain without specific indications.
    Unnecessary imaging in the first six weeks after pain begins may reveal incidental findings that divert attention and increase risk of unhelpful surgery. Clinical indications include history of cancer with potential metastases, known aortic aneurysm and progressive neurologic deficit.
  2. Don’t prescribe opioid analgesics as first-line therapy to treat chronic non-cancer pain.
    Physicians should first consider multimodal therapy, including non-drug treatments such as behavioral and physical therapies. Medication such as NSAIDs and anticonvulsants should be trialed prior to commencing opioids.
  3. Don’t prescribe opioid analgesics as long-term therapy to treat chronic non-cancer pain until risks are considered and discussed with the patient.
    Physicians should inform patients of risks including addiction, and physicians and patients should sign written agreements identifying each party’s responsibilities and consequences of non-compliance. Physicians should be cautious in co-prescribing opioids and benzodiazepines, and should proactively evaluate side effects such as constipation and low testosterone or estrogen.
  4. Don’t use intravenous sedation for diagnostic and therapeutic nerve blocks, or joint injections as a default practice.
    When possible, diagnostic procedures, therapeutic nerve blocks and joint injections should be performed with local anesthetic alone rather than with propofol, midazolam or ultrashort-acting opioid infusions. Intravenous sedation can be used after evaluation and discussion of risks, including interference in assessing acute pain-relieving effects of the procedure and potential for false positive responses. ASA Standards for Basic Anesthetic Monitoring should be followed in cases where moderate or deep sedation is provided or anticipated.
  5. Avoid irreversible interventions for non-cancer pain that carry significant costs and/or risks.
    Irreversible interventions such as peripheral chemical neurolytic blocks or peripheral radiofrequency ablation may carry significant long-term risks of weakness, numbness or increased pain.
Members of the ASA Committee on Pain Medicine submitted recommendations for this list, which were then voted on and researched to provide supporting evidence. 
 
For more information: www.asahq.org, www.choosingwisely.org

Related Content

News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
News | FDA

Mar. 9, 2026 — GE HealthCare's View, the powerful viewer within the Genesis Radiology Workspace, has received 510(k) ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | HIMSS

March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...

Time March 06, 2026
arrow
News | Radiology Business

March 5, 2026 — Cassling is now accepting applications for the 2026 Imaging for Impact Award, a national recognition ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
Subscribe Now